News
4d
Barchart on MSNRegeneron Pharmaceuticals Earnings Preview: What to ExpectRegeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...
4d
Zacks Investment Research on MSNRegeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseThe market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...
S&P 500 EPS growth is expected to come in at 4.8% for Q2, which would be the lowest growth rate since Q4 2023.
Regeneron: Down 18% in May Biotech giant Regeneron(NASDAQ: REGN) was on track for a quiet May, holding almost exactly steady with just a couple of days left in the month.
Regeneron Q1 2025 earnings presentation From Dupixent, Q1 2025 saw $1.53 billion in revenue, as the drug achieved global net sales, split with Sanofi, of $3.7 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results